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Background/aim: Dendritic cell-based vaccine therapy for renal cell carcinoma is effective but requires improvement. Here we explored
whether combination therapy with dendritic cell-based vaccine and anti-CD69 antibody can enhance antitumor efficacy in renal cell
carcinoma-bearing mice.
Materials and methods: Balb/c mice were challenged subcutaneously with murine renal cell carcinoma (Renca) cells. On day 3 after
tumor cell inoculation, tumor-bearing mice either were left untreated or were treated with Renca tumor lysate-pulsed dendritic cells
(i.e. dendritic cell-based vaccine), anti-CD69 antibody, or a combination of Renca tumor lysate-pulsed dendritic cells with anti-CD69
antibody. The mice were sacrificed on day 28. Tumor volume was measured for analysis of antitumor efficacy. Spleens were excised
to evaluate antitumor immunological responses by measuring the proliferation and activation of T cells, which have the capacity to
recognize and destroy tumor cells.
Results: Combination treatment with Renca tumor lysate-pulsed dendritic cells and anti-CD69 antibody resulted in significant decreases
in tumor volume and significant increases in T-cell proliferation and activity, compared with no treatment or either treatment alone.
Conclusion: These findings indicate that anti-CD69 antibody can potentiate antitumor efficacy of dendritic cell-based vaccine. The
augmented therapeutic efficacy conferred by the combination therapy may be associated with increased T-cell proliferation and activity.
Key words: Dendritic cell, cancer vaccine, CD69, monoclonal antibody, renal cell carcinoma model

1. Introduction
Renal cell carcinoma accounts for 4% of all malignant
tumors (1) and has an incidence of about 8–9 persons
per 100,000 each year, which is increasing (2). There is
no obvious symptom in the early stage of this cancer. As a
result, approximately 25%–30% of patients exhibit tumor
metastasis at first diagnosis and lose the opportunity for
surgery (3). Although patients with primarily localized
renal cell carcinoma can be successfully treated by partial
or radical nephrectomy, one third of cases will subsequently
develop metastases (4,5). Therapy of metastatic renal
cell carcinoma is particularly difficult because of its poor
response to radiotherapy or chemotherapy. Therefore, the
prognosis for patients with metastatic renal cell carcinoma
is poor, and the survival rate for 5 years is less than 10%

(6). These lead to a rising demand for other treatment
modalities.
Prospective studies note spontaneous regression rates
of up to 7% in patients with metastatic renal cell carcinoma
(7,8). In addition, immunohistochemical studies of renal
cell carcinoma often reveal tumor-infiltrating dendritic
cells and T lymphocytes able to recognize and kill tumor
cells (9). Therefore, renal cell carcinoma is considered
an immunogenic tumor. These findings also lead to
attempts to develop immunotherapeutic strategies using
immunostimulatory cytokines such as interleukin-2 and
interferon-α (10). It has been reported that treatment
with interleukin-2 and interferon-α can induce antitumor
activity in less than 20% of patients with metastatic renal
cell carcinoma, but is associated with a high incidence
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of toxic side effects such as lung edema, hypertension,
and hepatic and renal injury (10). Consequently, novel
therapeutic agents with more effectiveness and less toxicity
are needed.
Targeted therapy has revolutionized treatment for
metastatic renal cell carcinoma in the past decade.
Nowadays, there are seven approved targeted agents
regarded as standard therapy for metastatic renal cell
carcinoma: the monoclonal antibody to vascular endothelial
growth factor (VEGF) bevacizumab; the VEGF receptor
tyrosine kinase inhibitors (VEGFr-TKIs) pazopanib,
sunitinib, axitinib, and sorafenib; and the mammalian
target of rapamycin (mTOR) inhibitors temsirolimus and
everolimus (11,12). These targeted agents have markedly
improved treatment outcome (13). However, they rarely
achieve durable complete responses, and patients with
metastatic renal cell carcinoma eventually develop
resistance to targeted therapy (13). In addition, treatment
with targeted agents is frequently accompanied by various
side effects such as hypertension, hand-foot syndrome,
nausea, diarrhea, and fatigue (13). These observations
prompt consideration of new therapeutic approaches for
metastatic renal cell carcinoma.
More recently, emphasis has shifted to the use
of dendritic cell-based vaccine to treat patients with
metastatic renal cell carcinoma. Dendritic cells are the
most powerful antigen-presenting cells and play a critical
role in the induction of T-cell immune responses (14).
Dendritic cells have the unique ability to process and
present antigens derived from tumor cells to both naive
CD4+ and CD8+ T cells. The interaction between T cells
and dendritic cells results in activation and proliferation
of T cells. Activated CD8+ T cells become cytotoxic T
lymphocytes with the ability to recognize and kill tumor
cells expressing the same antigen on the cell surface (15).
Activated CD4+ T cells can provide help for CD8+ T cell
activation by secreting interleukin-2 (16). A total of 166
patients with metastatic renal cell carcinoma were treated
with dendritic cell-based vaccine in 11 clinical trials (17).
Clinical responses to vaccine were evaluated according
to the World Health Organization criteria (18): complete
response was defined as complete disappearance of tumor,
partial response was defined as ≥50% reduction in the
product of two longest perpendicular diameters of tumor
without the appearance of new metastases, stable disease
was defined as <50% decrease to <25% increase in tumor
size, and progressive disease was defined as ≥25% increase
in tumor size or the appearance of new metastases. Among
the 166 patients who finished therapy, 77 (46%) had clinical
response with 6 complete responses, 13 partial responses,
and 58 disease stabilizations (17). Treatment with dendritic
cell-based vaccine was only accompanied by mild adverse
effects such as local reactions at the injection site, flu-like

symptoms, and fever. Although dendritic cell vaccination
was proven to be safe and effective in clinical trials, the
clinical efficacy remained limited. Approaches to improve
these immune responses induced by dendritic cell-based
vaccine will strengthen the clinical efficacy of this vaccine.
CD69 is a type II transmembrane protein and belongs
to the C-type lectin superfamily (19). Activation of T-cells
leads to upregulated expression of CD69 on the cell surface
(20). CD69 acts as a co-stimulatory molecule for T-cell
activation and proliferation (21). Cross-linking of CD69 by
anti-CD69 monoclonal antibody can induce activation and
proliferation of T cells, thereby promoting T-cell effector
functions (22). We postulated that dendritic cell-based
vaccine and anti-CD69 antibody may act as therapeutically
synergistic partners against renal cell carcinoma. This
hypothesis is based on the following reasons. Dendritic
cell-based vaccine presents tumor antigen to T cells and
stimulates T cell activation. CD69 expression on T cells is
upregulated after T cell activation. Subsequent addition of
anti-CD69 antibody further induces T-cell activation and
proliferation via cross-linking of CD69 on T cells, thereby
increasing anticancer efficacy. To test this hypothesis, we
evaluated the combined efficacy of dendritic cell-based
vaccine with anti-CD69 antibody in the treatment of
murine renal cell carcinoma.
2. Materials and methods
2.1. Mice
Balb/c mice were purchased from Shanghai Laboratory
Animal Center (Shanghai City, China) and housed under
specific pathogen-free conditions. They had free access
to standard rodent chow and water. Mice were used for
experiments at the age of 8–10 weeks. The Animal Use and
Care Committee at our college approved the protocol for
all animal experiments, which conformed to the Principles
of Laboratory Animal Care published by the US National
Institutes of Health.
2.2. Generation of dendritic cell-based vaccine
Dendritic cell-based vaccine was generated from bone
marrow progenitors as described by Lim et al (23). In brief,
erythrocyte-depleted bone marrow cells of Balb/c mice
were cultured in RPMI-1640 medium supplemented with
2 mmol/L fresh L-glutamine, 10% heated-inactivated fetal
bovine serum (FBS), 100 µg/mL streptomycin, 100 units/
mL penicillin (all from Life Technologies, Grand Island,
NY, USA), 10 ng/mL recombinant mouse interleukin-4
(rm IL-4)(R&D Systems, Minneapolis, MN, USA), and
10 ng/mL recombinant mouse granulocyte-macrophage
colony-stimulating factor (rm GM-CSF) (R&D Systems).
On day 2, nonadherent cells were removed by washing.
The adherent cells were cultured in fresh RPMI-1640
medium supplemented with 10% heat-inactivated FBS, 10
ng/mL rm GM-CSF, and 10 ng/mL rm IL-4. The cultures

659

WEI et al. / Turk J Med Sci
were fed every other day by removing half of the medium
and replacing it with fresh RPMI-1640 medium containing
10% heat-inactivated FBS, 10 ng/mL rm GM-CSF, and 10
ng/mL rm IL-4. On day 7, suspended and loosely attached
cells (i.e. immature dendritic cells) were collected. The
murine renal cell carcinoma (Renca) cell line, syngeneic
to Balb/c mice, was purchased from the American Type
Culture Collection (Manassas, VA, USA). For preparation
of tumor lysate, Renca tumor cells were suspended in
phosphate-buffered saline and subjected to four successive
cycles of rapid freezing in liquid nitrogen and thawing
in a 37 °C water bath. In order to induce dendritic cell
maturation, immature dendritic cells were incubated
with Renca tumor cell lysate at a tumor cell equivalent to
dendritic cell ratio of 3:1 in RPMI-1640 medium. After
8 h of culture, dendritic cell further maturation could
be achieved by adding 10 ng/mL recombinant mouse
tumor necrosis factor-α (R&D Systems) and 10 ng/mL
recombinant mouse interferon-γ (R&D Systems). After
culture for 16 h, Renca tumor lysate-pulsed dendritic cells
(i.e. mature dendritic cells) were harvested and used as
dendritic cell-based vaccine in our study. Dendritic cells
were verified by phenotypic analysis.
2.3. Immunophenotypic analysis of dendritic cells by
flow cytometry
Immature and mature dendritic cells were collected,
immunostained with fluorescein isothiocyanateconjugated anti-CD11c (dendritic cell marker) monoclonal
antibody (BD PharMingen, San Diego, CA, USA), and
phycoerythrin-conjugated anti-CD83 (maturation marker
of dendritic cells) monoclonal antibody (BD PharMingen),
and then analyzed by flow cytometry for expressions of
CD11c and CD83 on the cell surface.
2.4. Analysis of CD69 expression on T cells
Balb/c mice either were left untreated or were immunized
subcutaneously with Renca tumor lysate-pulsed dendritic
cells (1 × 106). Some of the mice were killed at 24-h
intervals and their spleens were excised. Cell suspensions
were prepared from the spleens. T cells were purified by the
Magnetic Activated Cell Sorting device (Miltenyi Biotec,
Auburn, CA, USA), using the T-cell isolation kit according
to the manufacturer’s protocol (Miltenyi Biotec). Purified T
cells were immunostained with fluorescein isothiocyanateconjugated anti-CD3 (T-cell marker) monoclonal antibody
(BD PharMingen) and phycoerythrin-conjugated antiCD69 monoclonal antibody (BD PharMingen), and then
analyzed by flow cytometry for CD69 expression.
2.5. Renal cell carcinoma model and therapeutic protocol
On day 0, Balb/c mice were challenged subcutaneously
with 5 × 105 Renca viable tumor cells in the right flank.
On day 3, tumor-bearing mice were divided into 4 groups
with 10 mice in each group: control, dendritic cell-treated,
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antibody-treated, and combination-treated groups. Mice
in the control group received no treatment. The dendritic
cell-treated group underwent subcutaneous injection of
Renca tumor lysate-pulsed dendritic cells (1 × 106) in the
left flank on days 3 and 10. In the antibody-treated group,
anti-CD69 monoclonal antibody (100 µg; R&D Systems)
was injected intraperitoneally on days 3 and 10. Mice in the
combination therapy group received both subcutaneous
administration of Renca tumor lysate-pulsed dendritic
cells (1 × 106) on day 3 and intraperitoneal injection of
anti-CD69 monoclonal antibody (100 μg) on day 7. The
tumors were measured twice a week using mechanical
calipers in two dimensions. Tumor volume was calculated
by the formula (A × B2)/2, where A is the longest diameter
and B is the next longest diameter perpendicular to A. The
mice were sacrificed on day 28.
2.6. Determination of T cell proliferation
Spleens were collected from control (untreated) or variously
treated mice 28 days after tumor implantation. T cells were
purified from splenocytes by the use of a T cell isolation
kit (Miltenyi Biotec). Purified T cells were seeded into 96well round-bottom plates (1 × 105 per well) together with
1 × 104 Renca tumor lysate-pulsed dendritic cells. After
incubation for 4 days, cultures were pulsed for 16 h with
1 µCi [3H]thymidine (PerkinElmer, Waltham, MA, USA).
The cells were harvested on glass microfiber filters with a
cell harvester. T cell proliferative response was determined
by measuring [3H]thymidine incorporation using a liquid
scintillation counter. The results were expressed as counts
per minute.
2.7. Cytotoxicity assessment
Cell-mediated cytotoxicity was determined using a
standard 4-h 51Cr release assay. In brief, Renca tumor cells
were used as target cells and incubated with Na251CrO4
(PerkinElmer) for 1 h at 37 °C. Control (untreated) or
variously treated mice were killed 28 days after tumor
challenge and their spleens were harvested. CD8+ T cells
were purified from splenocytes by the use of a CD8+ T cell
isolation kit (Miltenyi Biotec) and were co-cultured with
Renca tumor lysate-pulsed dendritic cells at a ratio of 10:1.
After 5 days, the activated CD8+ T cells (effector cells)
were collected, washed twice, and co-incubated in roundbottom 96-well plates for 4 h with 51Cr-labeled Renca tumor
cells (target cells) at a 100:1 (effector:target cell ratio). The
51
Cr release was measured in culture supernatants with
a gamma counter. The percentage of target cell-specific
lysis was calculated as follows: [(experimental 51Cr release
– spontaneous 51Cr release)/(maximal 51Cr release –
spontaneous 51Cr release)] × 100. The amount of maximal
51
Cr release was determined by incubating target cells in
1% Triton X-100 (Sigma-Aldrich, St. Louis, MI, USA).
The amount of spontaneous 51Cr release was assessed by
incubation of target cells in medium alone.
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2.8. Detection of interleukin-2 by enzyme-linked
immunosorbent assay
Twenty-eight days after tumor challenge, spleens were
collected from control (untreated) or variously treated
mice. CD4+ T cells were purified from splenocytes by the
use of a CD4+ T cell isolation kit (Miltenyi Biotec), and
were stimulated in vitro with Renca tumor lysate-pulsed
dendritic cells at an effector/stimulator ratio of 10:1
for 24 h at 37 °C. Cell-free supernatants were harvested
and analyzed for secreted amount of interleukin-2
using an enzyme-linked immunosorbent assay kit (BD
PharMingen).
2.9. Statistical analysis
All data were presented as the mean ± standard deviation.
One-way analysis of variance with Student–Newman–
Keuls test was used for the data comparisons among the
groups. Statistical significance was defined as P < 0.05.
The data were analyzed by GraphPad Prism 4.0 software
(GraphPad Software Inc., San Diego, CA, USA).
3. Results
3.1. Surface phenotype of dendritic cell
As shown in Figure 1, cultured cells expressed high levels
of CD11c, which is a typical dendritic cell marker. These
results provide evidence that cultured cells are dendritic
cells. To determine the maturation status of dendritic
cells, we explored the expression of the maturation marker

CD83. Unpulsed dendritic cells expressed low levels of
CD83. These results indicate that unpulsed dendritic cells
are immature dendritic cells. In contrast, Renca tumor
lysate-pulsed dendritic cells showed high expression of
CD83, suggesting that these cells are mature dendritic
cells.
3.2. Renca tumor lysate-pulsed dendritic cell
immunization modulates CD69 expression on T cells
CD69 expression on T cells was assessed in the spleen
before and after immunization of mice with Renca tumor
lysate-pulsed dendritic cells. As depicted in Figure 2, CD69
expression on T cells was negligible before immunization.
However, Renca tumor lysate-pulsed dendritic cell
immunization induced upregulation of CD69 expression
on T cells.
3.3. Renca tumor lysate-pulsed dendritic cells in
combination with anti-CD69 antibody highly increases
the therapeutic efficacy
Tumor size is presented in Figure 3. Tumor volume in
Renca tumor lysate-pulsed dendritic cells or anti-CD69
antibody-only-treated mice was significantly reduced
in comparison with the control (untreated) mice (P <
0.05). The combination treatment with Renca tumor
lysate-pulsed dendritic cells and anti-CD69 antibody
caused a much greater reduction in tumor volume than
either treatment alone (P < 0.05), showing a synergistic
antitumor effect of the combination therapy.

Figure 1. Dendritic cell characterization. Dendritic cells were cultured as described in the Materials and methods section. Immature and
mature dendritic cells were collected, immunostained with fluorescein isothiocyanate-conjugated anti-CD11c (dendritic cell marker)
monoclonal antibody and phycoerythrin-conjugated anti-CD83 (maturation marker of dendritic cells) monoclonal antibody, and then
analyzed by flow cytometry. Expression rates of CD11c and CD83 in unpulsed dendritic cells (i.e. immature dendritic cells) and Renca
tumor lysate-pulsed dendritic cells (i.e. mature dendritic cells) were 84.7% (i.e. 3.1% + 81.6%) and 3.1%, and 85.3% (i.e. 68.4% + 16.9%)
and 68.4%, respectively.
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Figure 2. CD69 expression is upregulated on T cells induced by Renca tumor lysate-pulsed dendritic cells. Balb/c mice either were
left untreated or were immunized subcutaneously with Renca tumor lysate-pulsed dendritic cells. Some of mice were sacrificed at
24-h intervals and their spleens were collected. T cells were purified from splenocytes and double immunostained with fluorescein
isothiocyanate-conjugated anti-CD3 (T-cell marker) monoclonal antibody and phycoerythrin-conjugated anti-CD69 monoclonal
antibody. CD69 expression on T cells was analyzed by flow cytometry. (A) CD69 expression on T cells 4 days after immunization or
no treatment. Approximately 2.1% of T cells expressed CD69 in untreated mice. However, 50.8% of T cells expressed CD69 4 days
after immunization of mice with Renca tumor lysate-pulsed dendritic cells. These results were representative of three independent
experiments. (B) Dynamic change in CD69 expression on T cells. The peak level of CD69 expression on T cells was observed 4 days after
immunization of mice with Renca tumor lysate-pulsed dendritic cells.
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Figure 3. Renca tumor lysate-pulsed dendritic cells and anti-CD69 antibody synergistically inhibit Renca tumor growth. On day 0,
Balb/c mice were inoculated subcutaneously with Renca tumor cells. On day 3, tumor-bearing mice were divided into 4 groups with
10 mice in each group. Mice in the control group received no treatment. The dendritic cell-treated group underwent subcutaneous
injection of Renca tumor lysate-pulsed dendritic cells on days 3 and 10. In the antibody-treated group, anti-CD69 antibody was injected
intraperitoneally on days 3 and 10. Mice in the combination therapy group received both subcutaneous administration of Renca tumor
lysate-pulsed dendritic cells on day 3 and intraperitoneal injection of anti-CD69 antibody on day 7. Tumor growth was monitored twice
a week. Mice were sacrificed on day 28. *: Value significantly different from control group (P < 0.05). #: Value significantly different from
other groups (P < 0.05).

3.4. Renca tumor lysate-pulsed dendritic cells and antiCD69 antibody combined treatment improves T-cell
proliferation
Renca tumor lysate-pulsed dendritic cells or antiCD69 antibody treatment significantly increased T-cell
proliferation compared with the control (untreated) group
(P < 0.05) (Figure 4). However, the combination therapy
with Renca tumor lysate-pulsed dendritic cells and antiCD69 antibody led to the greatest proliferation of T cells
(P < 0.05) (Figure 4).
3.5. Anti-CD69 antibody potentiates cytotoxic
T-lymphocyte activity induced by Renca tumor lysatepulsed dendritic cells
As depicted in Figure 5, therapy with Renca tumor lysatepulsed dendritic cells or anti-CD69 antibody significantly
increased CD8+ T-cell activity (P < 0.05), with the highest
increase in the combination treatment (P < 0.05).
3.6. Co-treatment with Renca tumor lysate-pulsed
dendritic cells and anti-CD69 antibody results in
enhanced production of interleukin-2
As shown in Figure 6, mice treated with Renca tumor
lysate-pulsed dendritic cells or anti-CD69 antibody alone

showed a significant increase in interleukin-2 level in
comparison with the control (untreated) mice (P < 0.05).
However, co-treatment with Renca tumor lysate-pulsed
dendritic cells and anti-CD69 antibody resulted in higher
interleukin-2 level than any other groups (P < 0.05).
4. Discussion
Renal cell carcinoma cells are known to secrete both
interleukin-10 and transforming growth factor-β (24).
These cytokines inhibit the differentiation and maturation
of dendritic cells in vivo, as well as their function to
present tumor antigen, and to stimulate T lymphocytes,
thereby reducing antitumor immunity (24). Therefore,
the approach to culture dendritic cells in vitro has been
developed recently. Immature dendritic cells can be
obtained in vitro by culturing bone marrow cells in the
presence of interleukin-4 and granulocyte-macrophage
colony-stimulating factor (23). Further maturation can be
achieved by adding tumor antigen and cytokines such as
interferon-γ, tumor necrosis factor-α, and interleukin-1β
(23). Our data showed that cultured cells highly expressed
CD11c (dendritic cell marker) (Figure 1), suggesting that
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Figure 4. T-cell proliferation in mice treated with Renca tumor lysate-pulsed dendritic cells and anti-CD69 antibody. Renca tumorbearing mice (10 per group) either were left untreated or were treated with Renca tumor lysate-pulsed dendritic cells, anti-CD69
antibody, or combination of Renca tumor lysate-pulsed dendritic cells with anti-CD69 antibody. T cells were purified from splenocytes
of control (untreated) or variously treated mice and were cocultured with Renca tumor lysate-pulsed dendritic cells in 96-well plates.
After 4 days, 1 µCi [3H]thymidine was added to each well for an additional 16 h. T-cell proliferative response was determined by
measuring [3H]thymidine incorporation. Results were expressed as counts per minute.*: Value significantly different from control group
(P < 0.05). #: Value significantly different from other groups (P < 0.05).

Figure 5. Effect of Renca tumor lysate-pulsed dendritic cells and anti-CD69 antibody on cytotoxic T-lymphocyte activity. CD8+ T cells
purified from splenocytes of Renca tumor-bearing mice (10 per group), which either were left untreated or were treated with Renca
tumor lysate-pulsed dendritic cells, anti-CD69 antibody, or Renca tumor lysate-pulsed dendritic cells plus anti-CD69 antibody, were
seeded into 96-well plates together with Renca tumor lysate-pulsed dendritic cells. After 5 days, the activated CD8+ T cells (effector cells)
were collected and coincubated with 51Cr-labeled Renca tumor cells (target cells) at effector/target cell ratio of 100:1 for 4 h. Cytotoxic
T-lymphocyte activity against Renca tumor cells was determined by the 51Cr release assay. Results are shown as the percentage of target
cell lysis. *: Value significantly different from control group (P < 0.05). #: Value significantly different from other groups (P < 0.05).
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Figure 6. Evaluation of interleukin-2 production in Renca tumor lysate-pulsed dendritic cells + anti-CD69 antibody-treated mice.
Renca tumor-bearing mice (10 per group) either were left untreated or were treated with Renca tumor lysate-pulsed dendritic cells,
anti-CD69 antibody, or combination of Renca tumor lysate-pulsed dendritic cells with anti-CD69 antibody. CD4+ T cells were purified
from splenocytes of control (untreated) or variously treated mice, and were cocultured with Renca tumor lysate-pulsed dendritic cells.
Twenty-four hours later, cell-free supernatants were harvested and analyzed for secreted amount of interleukin-2 using an enzymelinked immunosorbent assay kit. *: Value significantly different from control group (P < 0.05). #: Value significantly different from other
groups (P < 0.05).

cultured cells are dendritic cells. The maturation status of
dendritic cells in tumor immunotherapy affects not only
immune response but also clinical outcome. Several pilot
clinical trials indicate that vaccination of mature dendritic
cells is associated with stronger immune response and
better clinical outcome than vaccination with immature
dendritic cells (25). These findings provide a scientific
rationale for the use of mature dendritic cells (i.e. Renca
tumor lysate-pulsed dendritic cells) in the present study.
The mature dendritic cells were identified by their high
expression of CD83, which is a typical maturation marker
of dendritic cells (Figure 1).
Dendritic cell-based vaccine is an important
immunotherapy for patients with metastatic renal cell
carcinoma. Many clinical trials have proven it to be
effective, but only low clinical efficacy has been observed
to date (17). Based on the reasons as described in the
Introduction section, we hypothesized that combination
of dendritic cell-based vaccine and anti-CD69 antibody
may enhance clinical efficacy. In the present study, we
found that CD69 expression increased on T cells after
immunization of mice with Renca tumor lysate-pulsed
dendritic cells (i.e. dendritic cell-based vaccine) (Figure
2). These data suggest that Renca tumor lysate-pulsed
dendritic cells induce T-cell activation, and the activated
T cells upregulate CD69 expression. These findings

provide a scientific rationale for subsequent use of antiCD69 antibody. Furthermore, we observed that CD69
expression on T cells reached a peak level on day 4 after
immunization of mice with Renca tumor lysate-pulsed
dendritic cells and then gradually declined (Figure 2B).
Therefore, mice in the combined therapy group received
an intraperitoneal injection of anti-CD69 antibody 4
days after immunization with Renca tumor lysate-pulsed
dendritic cells. The combination treatment resulted in a
significant decrease in tumor volume in comparison with
either treatment alone (Figure 3). These results confirm
our hypothesis that combination therapy can achieve a
synergistic effect and increase therapeutic efficacy.
The primary objective of immune monitoring after
dendritic cell-based vaccination is to find the association
between vaccine-induced immune response and clinical
outcome. Numerous assays for analysis of immune
response are available. Frequently used immunoassays
include enzyme-linked immunosorbent assay for detection
of interleukin-2, cytotoxicity test, T-cell proliferation
assay, delayed-type hypersensitivity skin test, and so on.
In the current study, the combination treatment with
Renca tumor lysate-pulsed dendritic cells and anti-CD69
antibody induced a much higher T-cell proliferation than
either monotherapy (Figure 4), implying that combined
therapy increases T-cell proliferation. In addition,
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significantly stronger cytotoxic T-lymphocyte activity was
observed in mice that underwent combination therapy
than those treated with either agent alone (Figure 5). These
data demonstrate that combination treatment enhances
CD8+ T-cell activity to recognize and destroy tumor
cells. Mice immunized with Renca tumor lysate-pulsed
dendritic cells plus anti-CD69 antibody showed a higher
interleukin-2 level in comparison with mice immunized
with either agent singly (Figure 6). These results suggest
that combined treatment improves CD4+ T-cell activity
to release cytokine interleukin-2. It has been shown that
interleukin-2 production can increase CD8+ T-cell activity
(16). Taken together, these findings indicate that combined
treatment induces enhanced T-cell proliferation and
activity. T cells have the ability to recognize and kill tumor
cells (15,16). Moreover, combination therapy significantly
inhibits tumor growth in comparison with either treatment
alone, and thus potentiates antitumor efficacy as discussed
above. When all these findings are taken together, we
think that the augmented antitumor efficacy conferred
by combination therapy may be associated with increased
T-cell proliferation and activity.
Many studies have demonstrated the effectiveness
of dendritic cells pulsed with tumor antigens for cancer
immunotherapy (17). Tumor antigens have various forms,
such as tumor lysate, apoptotic tumor bodies, tumorderived exosomes, tumor RNA or DNA, or peptide
antigens (17). The choice of antigenic material is one of
the most crucial aspects of designing an effective dendritic
cell-based immunotherapeutic protocol. In our study,

tumor lysate was selected as antigenic material. The
selection of tumor lysate as antigenic material has two
important advantages. Tumor lysate generally provides the
whole set of tumor antigens. Consequently, it can induce
a full immune response against multiple targets on the
tumor cells, which diminishes the likelihood for tumor
escape from immunological surveillance. Moreover, the
selection of tumor lysate as antigenic material eliminates
the requirement to identify and characterize the tumor
antigens. For some tumors in which there is a lack of wellcharacterized tumor antigens, the use of tumor lysate may
be the most practical method.
In conclusion, we have demonstrated for the first time
that anti-CD69 antibody can potentiate antitumor efficacy
of dendritic cell-based vaccine in renal cell carcinomabearing mice. The augmented therapeutic efficacy conferred
by the combined therapy with dendritic cell-based vaccine
and anti-CD69 antibody may be associated with increased
T-cell proliferation and activity. The combined therapy
may represent a new immunotherapeutic approach for
patients with renal cell carcinoma. This new approach
should be further evaluated in clinical trials.
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